BindingDB logo
myBDB logout

Patent code US9790229

Compile Data Set for Download or QSAR

Found 360 hits of Enzyme Inhibition Constant Data   
Target/Host
(Institution)		LigandTarget/Host
Links		Ligand
Links		Trg + Lig
Links		Ki
nM		ΔG°
kJ/mole		IC50
nM		Kd
nM		EC50/IC50
nM		koff
s-1		kon
M-1s-1		pHTemp
°C
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348562
PNG
(US9790229, Compound 285)
Show SMILES Fc1cc(Cl)cc(NC2CCCN([C@@H]3CCCN(C3)c3c(cnc4[nH]ccc34)C#N)C2=O)c1
Show InChI InChI=1S/C24H24ClFN6O/c25-16-9-17(26)11-18(10-16)30-21-4-2-8-32(24(21)33)19-3-1-7-31(14-19)22-15(12-27)13-29-23-20(22)5-6-28-23/h5-6,9-11,13,19,21,30H,1-4,7-8,14H2,(H,28,29)/t19-,21?/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348591
PNG
(US9790229, Compound 314)
Show SMILES Nc1ncnc(N2CCC[C@H](C2)N2CCC[C@@H](Nc3cc(F)cc(Cl)c3)C2=O)c1F
Show InChI InChI=1S/C20H23ClF2N6O/c21-12-7-13(22)9-14(8-12)27-16-4-2-6-29(20(16)30)15-3-1-5-28(10-15)19-17(23)18(24)25-11-26-19/h7-9,11,15-16,27H,1-6,10H2,(H2,24,25,26)/t15-,16-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348593
PNG
(US9790229, Compound 316)
Show SMILES Fc1cc(Cl)cc(N[C@@H]2CCCN([C@@H]3CCCN(C3)c3ncnc4[nH]ccc34)C2=O)c1
Show InChI InChI=1S/C22H24ClFN6O/c23-14-9-15(24)11-16(10-14)28-19-4-2-8-30(22(19)31)17-3-1-7-29(12-17)21-18-5-6-25-20(18)26-13-27-21/h5-6,9-11,13,17,19,28H,1-4,7-8,12H2,(H,25,26,27)/t17-,19-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348606
PNG
(US9790229, Compound 329)
Show SMILES Nc1ncnc(N2CC[C@@H]([C@H](C2)N2CCCC(Nc3cc(F)cc(Cl)c3)C2=O)C(F)(F)F)c1F
Show InChI InChI=1S/C21H22ClF5N6O/c22-11-6-12(23)8-13(7-11)31-15-2-1-4-33(20(15)34)16-9-32(5-3-14(16)21(25,26)27)19-17(24)18(28)29-10-30-19/h6-8,10,14-16,31H,1-5,9H2,(H2,28,29,30)/t14-,15?,16-/m0/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348616
PNG
(US9790229, Compound 339)
Show SMILES FC(F)(F)[C@H]1CCN(C[C@@H]1N1CCCC(Nc2cc(Cl)cc(Cl)c2)C1=O)c1ncnc2[nH]ccc12
Show InChI InChI=1S/C23H23Cl2F3N6O/c24-13-8-14(25)10-15(9-13)32-18-2-1-6-34(22(18)35)19-11-33(7-4-17(19)23(26,27)28)21-16-3-5-29-20(16)30-12-31-21/h3,5,8-10,12,17-19,32H,1-2,4,6-7,11H2,(H,29,30,31)/t17-,18?,19-/m0/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348327
PNG
(US9790229, Compound 50)
Show SMILES Clc1cccc(N2CCCC2)c1NC(=O)Nc1cccc(c1)C1CCCN(C1)c1ncnc2[nH]ccc12
Show InChI InChI=1S/C28H30ClN7O/c29-23-9-4-10-24(35-13-1-2-14-35)25(23)34-28(37)33-21-8-3-6-19(16-21)20-7-5-15-36(17-20)27-22-11-12-30-26(22)31-18-32-27/h3-4,6,8-12,16,18,20H,1-2,5,7,13-15,17H2,(H,30,31,32)(H2,33,34,37)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348555
PNG
(US9790229, Compound 278)
Show SMILES Nc1ncnc(N2CCC[C@H](C2)N2CCCC(Nc3cc(Cl)cc(Cl)c3)C2=O)c1F
Show InChI InChI=1S/C20H23Cl2FN6O/c21-12-7-13(22)9-14(8-12)27-16-4-2-6-29(20(16)30)15-3-1-5-28(10-15)19-17(23)18(24)25-11-26-19/h7-9,11,15-16,27H,1-6,10H2,(H2,24,25,26)/t15-,16?/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348560
PNG
(US9790229, Compound 283)
Show SMILES Nc1ncnc(N2C[C@@H](O)C[C@H](C2)N2CCCC(Nc3cc(Cl)cc(Cl)c3)C2=O)c1F
Show InChI InChI=1S/C20H23Cl2FN6O2/c21-11-4-12(22)6-13(5-11)27-16-2-1-3-29(20(16)31)14-7-15(30)9-28(8-14)19-17(23)18(24)25-10-26-19/h4-6,10,14-16,27,30H,1-3,7-9H2,(H2,24,25,26)/t14-,15+,16?/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348582
PNG
(US9790229, Compound 305)
Show SMILES FC(F)(F)c1cc(Cl)cc(NC2CCCN([C@@H]3CCCN(C3)c3ncnc4[nH]ncc34)C2=O)c1
Show InChI InChI=1S/C22H23ClF3N7O/c23-14-7-13(22(24,25)26)8-15(9-14)30-18-4-2-6-33(21(18)34)16-3-1-5-32(11-16)20-17-10-29-31-19(17)27-12-28-20/h7-10,12,16,18,30H,1-6,11H2,(H,27,28,29,31)/t16-,18?/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348584
PNG
(US9790229, Compound 307)
Show SMILES FC(F)(F)c1cc(NC2CCCN([C@@H]3CCCN(C3)c3ncnc4[nH]ncc34)C2=O)cc(c1)C(F)(F)F
Show InChI InChI=1S/C23H23F6N7O/c24-22(25,26)13-7-14(23(27,28)29)9-15(8-13)33-18-4-2-6-36(21(18)37)16-3-1-5-35(11-16)20-17-10-32-34-19(17)30-12-31-20/h7-10,12,16,18,33H,1-6,11H2,(H,30,31,32,34)/t16-,18?/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348585
PNG
(US9790229, Compound 308)
Show SMILES Nc1ncnc(N2CCC[C@H](C2)N2CCCC(Nc3cc(Cl)cc(c3)C(F)(F)F)C2=O)c1F
Show InChI InChI=1S/C21H23ClF4N6O/c22-13-7-12(21(24,25)26)8-14(9-13)30-16-4-2-6-32(20(16)33)15-3-1-5-31(10-15)19-17(23)18(27)28-11-29-19/h7-9,11,15-16,30H,1-6,10H2,(H2,27,28,29)/t15-,16?/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348589
PNG
(US9790229, Compound 312)
Show SMILES Nc1ncnc(N2CCC[C@H](C2)N2CCC[C@H](Nc3cc(Cl)cc(c3)C(F)(F)F)C2=O)c1F
Show InChI InChI=1S/C21H23ClF4N6O/c22-13-7-12(21(24,25)26)8-14(9-13)30-16-4-2-6-32(20(16)33)15-3-1-5-31(10-15)19-17(23)18(27)28-11-29-19/h7-9,11,15-16,30H,1-6,10H2,(H2,27,28,29)/t15-,16+/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348594
PNG
(US9790229, Compound 317)
Show SMILES Fc1cc(Cl)cc(N[C@H]2CCCN([C@@H]3CCCN(C3)c3ncnc4[nH]ccc34)C2=O)c1
Show InChI InChI=1S/C22H24ClFN6O/c23-14-9-15(24)11-16(10-14)28-19-4-2-8-30(22(19)31)17-3-1-7-29(12-17)21-18-5-6-25-20(18)26-13-27-21/h5-6,9-11,13,17,19,28H,1-4,7-8,12H2,(H,25,26,27)/t17-,19+/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348627
PNG
(US9790229, Compound 350)
Show SMILES Nc1ncnc(N2CC[C@H]([C@@H](C2)N2CC=CC[C@@H](Nc3cc(F)cc(Cl)c3)C2=O)C(F)(F)F)c1F
Show InChI InChI=1S/C22H22ClF5N6O/c23-12-7-13(24)9-14(8-12)32-16-3-1-2-5-34(21(16)35)17-10-33(6-4-15(17)22(26,27)28)20-18(25)19(29)30-11-31-20/h1-2,7-9,11,15-17,32H,3-6,10H2,(H2,29,30,31)/t15-,16-,17-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348629
PNG
(US9790229, Compound 352)
Show SMILES Fc1cc(Cl)cc(NC2CCCN([C@H]3CN(CC[C@@H]3C(F)(F)F)c3ncnc4[nH]ccc34)C2=O)c1
Show InChI InChI=1S/C23H23ClF4N6O/c24-13-8-14(25)10-15(9-13)32-18-2-1-6-34(22(18)35)19-11-33(7-4-17(19)23(26,27)28)21-16-3-5-29-20(16)30-12-31-21/h3,5,8-10,12,17-19,32H,1-2,4,6-7,11H2,(H,29,30,31)/t17-,18?,19-/m0/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348552
PNG
(US9790229, Compound 275)
Show SMILES Fc1cc(Cl)cc(NC2CCCN([C@@H]3CCCN(C3)c3ncnc4[nH]ccc34)C2=O)c1
Show InChI InChI=1S/C22H24ClFN6O/c23-14-9-15(24)11-16(10-14)28-19-4-2-8-30(22(19)31)17-3-1-7-29(12-17)21-18-5-6-25-20(18)26-13-27-21/h5-6,9-11,13,17,19,28H,1-4,7-8,12H2,(H,25,26,27)/t17-,19?/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348577
PNG
(US9790229, Compound 300)
Show SMILES FC(F)(F)c1cc(Cl)cc(NC2CCCN([C@@H]3CCCN(C3)c3ncnc4[nH]ccc34)C2=O)c1
Show InChI InChI=1S/C23H24ClF3N6O/c24-15-9-14(23(25,26)27)10-16(11-15)31-19-4-2-8-33(22(19)34)17-3-1-7-32(12-17)21-18-5-6-28-20(18)29-13-30-21/h5-6,9-11,13,17,19,31H,1-4,7-8,12H2,(H,28,29,30)/t17-,19?/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348592
PNG
(US9790229, Compound 315)
Show SMILES Nc1ncnc(N2CCC[C@H](C2)N2CCC[C@@H](Nc3cc(Cl)cc(Cl)c3)C2=O)c1F
Show InChI InChI=1S/C20H23Cl2FN6O/c21-12-7-13(22)9-14(8-12)27-16-4-2-6-29(20(16)30)15-3-1-5-28(10-15)19-17(23)18(24)25-11-26-19/h7-9,11,15-16,27H,1-6,10H2,(H2,24,25,26)/t15-,16-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348611
PNG
(US9790229, Compound 334)
Show SMILES Nc1ncnc(N2CC[C@@H]([C@H](C2)N2CCCC(Nc3cc(Cl)cc(Cl)c3)C2=O)C(F)(F)F)c1F
Show InChI InChI=1S/C21H22Cl2F4N6O/c22-11-6-12(23)8-13(7-11)31-15-2-1-4-33(20(15)34)16-9-32(5-3-14(16)21(25,26)27)19-17(24)18(28)29-10-30-19/h6-8,10,14-16,31H,1-5,9H2,(H2,28,29,30)/t14-,15?,16-/m0/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348612
PNG
(US9790229, Compound 335)
Show SMILES Nc1ncnc(N2CC[C@H]([C@@H](C2)N2CCC[C@@H](Nc3cc(Cl)cc(Cl)c3)C2=O)C(F)(F)F)c1F
Show InChI InChI=1S/C21H22Cl2F4N6O/c22-11-6-12(23)8-13(7-11)31-15-2-1-4-33(20(15)34)16-9-32(5-3-14(16)21(25,26)27)19-17(24)18(28)29-10-30-19/h6-8,10,14-16,31H,1-5,9H2,(H2,28,29,30)/t14-,15-,16-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348624
PNG
(US9790229, Compound 347)
Show SMILES Nc1ncnc(N2CCC[C@H](C2)N2CC=CC[C@@H](Nc3cc(F)cc(Cl)c3)C2=O)c1F
Show InChI InChI=1S/C21H23ClF2N6O/c22-13-8-14(23)10-15(9-13)28-17-5-1-2-7-30(21(17)31)16-4-3-6-29(11-16)20-18(24)19(25)26-12-27-20/h1-2,8-10,12,16-17,28H,3-7,11H2,(H2,25,26,27)/t16-,17-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348632
PNG
(US9790229, Compound 355)
Show SMILES FC(F)(F)[C@H]1CCN(C[C@@H]1N1CC[C@@H](Nc2cc(Cl)cc(Cl)c2)C1=O)c1ncnc2[nH]ncc12
Show InChI InChI=1S/C21H20Cl2F3N7O/c22-11-5-12(23)7-13(6-11)30-16-2-4-33(20(16)34)17-9-32(3-1-15(17)21(24,25)26)19-14-8-29-31-18(14)27-10-28-19/h5-8,10,15-17,30H,1-4,9H2,(H,27,28,29,31)/t15-,16+,17-/m0/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348637
PNG
(US9790229, Compound 360)
Show SMILES Fc1cc(Cl)cc(NC2CCCN([C@@H]3CCCN(C3)c3ncnc4[nH]ncc34)C2=O)c1
Show InChI InChI=1S/C21H23ClFN7O/c22-13-7-14(23)9-15(8-13)27-18-4-2-6-30(21(18)31)16-3-1-5-29(11-16)20-17-10-26-28-19(17)24-12-25-20/h7-10,12,16,18,27H,1-6,11H2,(H,24,25,26,28)/t16-,18?/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348314
PNG
(US9790229, Compound 37)
Show SMILES O=C(Nc1cccc(c1)C1CCCN(C1)c1ncnc2[nH]ccc12)Nc1ccccc1N1CCCC1
Show InChI InChI=1S/C28H31N7O/c36-28(33-24-10-1-2-11-25(24)34-14-3-4-15-34)32-22-9-5-7-20(17-22)21-8-6-16-35(18-21)27-23-12-13-29-26(23)30-19-31-27/h1-2,5,7,9-13,17,19,21H,3-4,6,8,14-16,18H2,(H,29,30,31)(H2,32,33,36)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348326
PNG
(US9790229, Compound 49)
Show SMILES O=CNc1cccc(c1)C1CCCN(C1)c1ncnc2[nH]ccc12
Show InChI InChI=1S/C18H19N5O/c24-12-22-15-5-1-3-13(9-15)14-4-2-8-23(10-14)18-16-6-7-19-17(16)20-11-21-18/h1,3,5-7,9,11-12,14H,2,4,8,10H2,(H,22,24)(H,19,20,21)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
KEGG
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348389
PNG
(US9790229, Compound 112)
Show SMILES Fc1cc(F)c(NC(=O)Nc2csc(n2)C2CCCN(C2)c2ncnc3[nH]ncc23)c(c1)N1CCCC1
Show InChI InChI=1S/C24H25F2N9OS/c25-15-8-17(26)20(18(9-15)34-5-1-2-6-34)32-24(36)31-19-12-37-23(30-19)14-4-3-7-35(11-14)22-16-10-29-33-21(16)27-13-28-22/h8-10,12-14H,1-7,11H2,(H2,31,32,36)(H,27,28,29,33)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348390
PNG
(US9790229, Compound 113)
Show SMILES Nc1ncnc(N2CCCC(C2)c2nc(NC(=O)Nc3c(F)cc(F)cc3N3CCCC3)cs2)c1C#N
Show InChI InChI=1S/C24H25F2N9OS/c25-15-8-17(26)20(18(9-15)34-5-1-2-6-34)33-24(36)32-19-12-37-23(31-19)14-4-3-7-35(11-14)22-16(10-27)21(28)29-13-30-22/h8-9,12-14H,1-7,11H2,(H2,28,29,30)(H2,32,33,36)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348412
PNG
(US9790229, Compound 135)
Show SMILES OCCN1CCN(CC1c1cccc(NC(=O)Nc2c(F)cccc2N2CCCC2)c1)c1ncnc2[nH]ccc12
Show InChI InChI=1S/C29H33FN8O2/c30-23-7-4-8-24(36-11-1-2-12-36)26(23)35-29(40)34-21-6-3-5-20(17-21)25-18-38(14-13-37(25)15-16-39)28-22-9-10-31-27(22)32-19-33-28/h3-10,17,19,25,39H,1-2,11-16,18H2,(H,31,32,33)(H2,34,35,40)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
PDB
UniChem
PDB
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair		3D
3D Structure (crystal)
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348424
PNG
(US9790229, Compound 147)
Show SMILES Fc1ccc(NC(=O)Nc2cccc(c2)C2CCCN(C2)c2ncnc3[nH]ccc23)c(c1)N1CCCC1
Show InChI InChI=1S/C28H30FN7O/c29-21-8-9-24(25(16-21)35-12-1-2-13-35)34-28(37)33-22-7-3-5-19(15-22)20-6-4-14-36(17-20)27-23-10-11-30-26(23)31-18-32-27/h3,5,7-11,15-16,18,20H,1-2,4,6,12-14,17H2,(H,30,31,32)(H2,33,34,37)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348427
PNG
(US9790229, Compound 150)
Show SMILES O[C@H]1CN(C[C@@H]1O)c1ccccc1NC(=O)Nc1cccc(c1)C1CCCN(C1)c1ncnc2[nH]ccc12
Show InChI InChI=1S/C28H31N7O3/c36-24-15-35(16-25(24)37)23-9-2-1-8-22(23)33-28(38)32-20-7-3-5-18(13-20)19-6-4-12-34(14-19)27-21-10-11-29-26(21)30-17-31-27/h1-3,5,7-11,13,17,19,24-25,36-37H,4,6,12,14-16H2,(H,29,30,31)(H2,32,33,38)/t19?,24-,25-/m0/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348428
PNG
(US9790229, Compound 151)
Show SMILES CC(C)c1ccccc1NC(=O)Nc1cccc(c1)C1CCCN(C1)c1ncnc2[nH]ccc12
Show InChI InChI=1S/C27H30N6O/c1-18(2)22-10-3-4-11-24(22)32-27(34)31-21-9-5-7-19(15-21)20-8-6-14-33(16-20)26-23-12-13-28-25(23)29-17-30-26/h3-5,7,9-13,15,17-18,20H,6,8,14,16H2,1-2H3,(H,28,29,30)(H2,31,32,34)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348429
PNG
(US9790229, Compound 152)
Show SMILES OC[C@@H]1CCCN1c1ccccc1NC(=O)Nc1cccc(c1)C1CCCN(C1)c1ncnc2[nH]ccc12
Show InChI InChI=1S/C29H33N7O2/c37-18-23-9-5-15-36(23)26-11-2-1-10-25(26)34-29(38)33-22-8-3-6-20(16-22)21-7-4-14-35(17-21)28-24-12-13-30-27(24)31-19-32-28/h1-3,6,8,10-13,16,19,21,23,37H,4-5,7,9,14-15,17-18H2,(H,30,31,32)(H2,33,34,38)/t21?,23-/m0/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348596
PNG
(US9790229, Compound 319)
Show SMILES Nc1ncnc(N2CCC[C@H](C2)N2CCCC(Nc3ccccc3S(=O)(=O)c3ccccc3)C2=O)c1F
Show InChI InChI=1S/C26H29FN6O3S/c27-23-24(28)29-17-30-25(23)32-14-6-8-18(16-32)33-15-7-12-21(26(33)34)31-20-11-4-5-13-22(20)37(35,36)19-9-2-1-3-10-19/h1-5,9-11,13,17-18,21,31H,6-8,12,14-16H2,(H2,28,29,30)/t18-,21?/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348599
PNG
(US9790229, Compound 322)
Show SMILES FC(F)(F)[C@H]1CCN(C[C@@H]1N1CC[C@@H](Nc2cc(Cl)cc(Cl)c2)C1=O)c1ncnc2[nH]ccc12
Show InChI InChI=1S/C22H21Cl2F3N6O/c23-12-7-13(24)9-14(8-12)31-17-3-6-33(21(17)34)18-10-32(5-2-16(18)22(25,26)27)20-15-1-4-28-19(15)29-11-30-20/h1,4,7-9,11,16-18,31H,2-3,5-6,10H2,(H,28,29,30)/t16-,17+,18-/m0/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348618
PNG
(US9790229, Compound 341)
Show SMILES Nc1ncnc(N2CC[C@@H](F)[C@H](C2)N2CCC[C@@H](Nc3cc(F)cc(Cl)c3)C2=O)c1F
Show InChI InChI=1S/C20H22ClF3N6O/c21-11-6-12(22)8-13(7-11)28-15-2-1-4-30(20(15)31)16-9-29(5-3-14(16)23)19-17(24)18(25)26-10-27-19/h6-8,10,14-16,28H,1-5,9H2,(H2,25,26,27)/t14-,15-,16+/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348329
PNG
(US9790229, Compound 52)
Show SMILES C[C@@H]1CCCN1c1cccc(F)c1NC(=O)Nc1cccc(c1)C1CCCN(C1)c1ncnc2[nH]ccc12
Show InChI InChI=1S/C29H32FN7O/c1-19-6-4-15-37(19)25-11-3-10-24(30)26(25)35-29(38)34-22-9-2-7-20(16-22)21-8-5-14-36(17-21)28-23-12-13-31-27(23)32-18-33-28/h2-3,7,9-13,16,18-19,21H,4-6,8,14-15,17H2,1H3,(H,31,32,33)(H2,34,35,38)/t19-,21?/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348426
PNG
(US9790229, Compound 149)
Show SMILES O[C@@H]1CCN(C1)c1ccccc1NC(=O)Nc1cccc(c1)C1CCCN(C1)c1ncnc2[nH]ccc12
Show InChI InChI=1S/C28H31N7O2/c36-22-11-14-34(17-22)25-9-2-1-8-24(25)33-28(37)32-21-7-3-5-19(15-21)20-6-4-13-35(16-20)27-23-10-12-29-26(23)30-18-31-27/h1-3,5,7-10,12,15,18,20,22,36H,4,6,11,13-14,16-17H2,(H,29,30,31)(H2,32,33,37)/t20?,22-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348557
PNG
(US9790229, Compound 280)
Show SMILES Nc1ncnc(N2C[C@@H](F)C[C@H](C2)N2CCCC(Nc3cc(Cl)cc(Cl)c3)C2=O)c1F
Show InChI InChI=1S/C20H22Cl2F2N6O/c21-11-4-12(22)6-14(5-11)28-16-2-1-3-30(20(16)31)15-7-13(23)8-29(9-15)19-17(24)18(25)26-10-27-19/h4-6,10,13,15-16,28H,1-3,7-9H2,(H2,25,26,27)/t13-,15+,16?/m0/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348558
PNG
(US9790229, Compound 281)
Show SMILES C[C@H]1CCN(C[C@@H]1N1CCCC(Nc2cc(Cl)cc(Cl)c2)C1=O)c1ncnc(N)c1F
Show InChI InChI=1S/C21H25Cl2FN6O/c1-12-4-6-29(20-18(24)19(25)26-11-27-20)10-17(12)30-5-2-3-16(21(30)31)28-15-8-13(22)7-14(23)9-15/h7-9,11-12,16-17,28H,2-6,10H2,1H3,(H2,25,26,27)/t12-,16?,17-/m0/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348579
PNG
(US9790229, Compound 302)
Show SMILES FC(F)(F)c1cc(NC2CCCN([C@@H]3CCCN(C3)c3ncnc4[nH]ccc34)C2=O)cc(c1)C(F)(F)F
Show InChI InChI=1S/C24H24F6N6O/c25-23(26,27)14-9-15(24(28,29)30)11-16(10-14)34-19-4-2-8-36(22(19)37)17-3-1-7-35(12-17)21-18-5-6-31-20(18)32-13-33-21/h5-6,9-11,13,17,19,34H,1-4,7-8,12H2,(H,31,32,33)/t17-,19?/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348603
PNG
(US9790229, Compound 326)
Show SMILES Nc1ncnc(N2CC[C@H](O)[C@H](C2)N2CCC[C@@H](Nc3cc(Cl)cc(Cl)c3)C2=O)c1F
Show InChI InChI=1S/C20H23Cl2FN6O2/c21-11-6-12(22)8-13(7-11)27-14-2-1-4-29(20(14)31)15-9-28(5-3-16(15)30)19-17(23)18(24)25-10-26-19/h6-8,10,14-16,27,30H,1-5,9H2,(H2,24,25,26)/t14-,15+,16+/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348622
PNG
(US9790229, Compound 345)
Show SMILES Nc1ncnc(N2CCOCC(C2)N2CCCC(Nc3cc(F)cc(Cl)c3)C2=O)c1F
Show InChI InChI=1S/C20H23ClF2N6O2/c21-12-6-13(22)8-14(7-12)27-16-2-1-3-29(20(16)30)15-9-28(4-5-31-10-15)19-17(23)18(24)25-11-26-19/h6-8,11,15-16,27H,1-5,9-10H2,(H2,24,25,26)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348623
PNG
(US9790229, Compound 346)
Show SMILES Nc1ncnc(N2CCC[C@H](C2)N2CCCC[C@@H](Nc3cc(F)cc(Cl)c3)C2=O)c1F
Show InChI InChI=1S/C21H25ClF2N6O/c22-13-8-14(23)10-15(9-13)28-17-5-1-2-7-30(21(17)31)16-4-3-6-29(11-16)20-18(24)19(25)26-12-27-20/h8-10,12,16-17,28H,1-7,11H2,(H2,25,26,27)/t16-,17-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348626
PNG
(US9790229, Compound 349)
Show SMILES Nc1ncnc(N2CCC(C(C2)N2CC=CC[C@@H](Nc3cc(F)cc(Cl)c3)C2=O)C(F)(F)F)c1F
Show InChI InChI=1S/C22H22ClF5N6O/c23-12-7-13(24)9-14(8-12)32-16-3-1-2-5-34(21(16)35)17-10-33(6-4-15(17)22(26,27)28)20-18(25)19(29)30-11-31-20/h1-2,7-9,11,15-17,32H,3-6,10H2,(H2,29,30,31)/t15?,16-,17?/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348423
PNG
(US9790229, Compound 146)
Show SMILES Fc1cccc(N2CCCC2)c1NC(=O)Nc1cccc(c1)C1CCCN(C1)c1ncnc2[nH]ccc12
Show InChI InChI=1S/C28H30FN7O/c29-23-9-4-10-24(35-13-1-2-14-35)25(23)34-28(37)33-21-8-3-6-19(16-21)20-7-5-15-36(17-20)27-22-11-12-30-26(22)31-18-32-27/h3-4,6,8-12,16,18,20H,1-2,5,7,13-15,17H2,(H,30,31,32)(H2,33,34,37)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348431
PNG
(US9790229, Compound 154)
Show SMILES CC(C)c1cccc(C(C)C)c1NC(=O)Nc1cccc(c1)C1CCCN(C1)c1ncnc2[nH]ccc12
Show InChI InChI=1S/C30H36N6O/c1-19(2)24-11-6-12-25(20(3)4)27(24)35-30(37)34-23-10-5-8-21(16-23)22-9-7-15-36(17-22)29-26-13-14-31-28(26)32-18-33-29/h5-6,8,10-14,16,18-20,22H,7,9,15,17H2,1-4H3,(H,31,32,33)(H2,34,35,37)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348553
PNG
(US9790229, Compound 276)
Show SMILES Clc1cc(Cl)cc(NC2CCCN([C@@H]3CCCN(C3)c3ncnc4[nH]ccc34)C2=O)c1
Show InChI InChI=1S/C22H24Cl2N6O/c23-14-9-15(24)11-16(10-14)28-19-4-2-8-30(22(19)31)17-3-1-7-29(12-17)21-18-5-6-25-20(18)26-13-27-21/h5-6,9-11,13,17,19,28H,1-4,7-8,12H2,(H,25,26,27)/t17-,19?/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348556
PNG
(US9790229, Compound 279)
Show SMILES Nc1ncnc(N2C[C@@H](F)C[C@H](C2)N2CCCC(Nc3cc(F)cc(Cl)c3)C2=O)c1F
Show InChI InChI=1S/C20H22ClF3N6O/c21-11-4-12(22)6-14(5-11)28-16-2-1-3-30(20(16)31)15-7-13(23)8-29(9-15)19-17(24)18(25)26-10-27-19/h4-6,10,13,15-16,28H,1-3,7-9H2,(H2,25,26,27)/t13-,15+,16?/m0/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348559
PNG
(US9790229, Compound 282)
Show SMILES C[C@H]1CCN(C[C@@H]1N1CCCC(Nc2cccc(Cl)c2)C1=O)c1ncnc(N)c1F
Show InChI InChI=1S/C21H26ClFN6O/c1-13-7-9-28(20-18(23)19(24)25-12-26-20)11-17(13)29-8-3-6-16(21(29)30)27-15-5-2-4-14(22)10-15/h2,4-5,10,12-13,16-17,27H,3,6-9,11H2,1H3,(H2,24,25,26)/t13-,16?,17-/m0/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Tyrosine-protein kinase BTK


(Homo sapiens (Human))		BDBM348590
PNG
(US9790229, Compound 313)
Show SMILES Nc1ncnc(N2CCC[C@H](C2)N2CCC[C@H](Nc3cc(F)cc(Cl)c3)C2=O)c1F
Show InChI InChI=1S/C20H23ClF2N6O/c21-12-7-13(22)9-14(8-12)27-16-4-2-6-29(20(16)30)15-3-1-5-28(10-15)19-17(23)18(24)25-11-26-19/h7-9,11,15-16,27H,1-6,10H2,(H2,24,25,26)/t15-,16+/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



Sunesis Pharmaceuticals, Inc.; Biogen MA Inc.

US Patent


Assay Description
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...

US Patent US9790229 (2017)

More data for this
Ligand-Target Pair
Displayed 1 to 50 (of 360 total )  |  Next  |  Last  >>
* indicates data uncertainty>20%